Amazon gives shoes, purses a try with new stand-alone site
Bigger is better - At 15, super-sized Shoes still intent on winning
Ice fans give shoes the boot - Weather brings a rough but rare treat for area's skaters
If the shoe fits - Allen-Edmonds executive found the right pair to sell company
McKenna filling big shoes - Sophomore is third straight big presence; gets 12 of 32 in fourth
Omrix underwriters exercise green shoe option - The underwriting syndicate purchased 337,500 shares for $10.8 million
Prophet's name on shoes...Farwaniya store in dock
Shoe leather goes to save horses' hides - Girls raise $507 by pounding pavement for 8 animals rescued from abuse case
'Sport fusion' shoes are hot - They're kicking up companies' sales
Thrill of the chase requires the right footwear - Shoe collectors go to great lengths in time and cost to find rare versions, often done by artists -- and designed to change the market
Exclusive shoes
Omrix underwriters exercise green shoe option - The underwriting syndicate purchased 337,500 shares for $10.8 million

Omrix Biopharmaceuticals Ltd. (Nasdaq:OMRI) announced on Friday that the underwriters in the company's secondary offering have exercised their green shoe option in full. Omrix has a market cap of $560 million. The underwriting syndicate purchased 337,500 shares for $10.8 million. 235,109 shares were purchased from the company for $7.5 million and 102,391 shares from a selling stockholder, apparently Omrix CEO Robert Taub, for $3.3 million.

UBS Investment Bank and Citigroup acted as the joint book-running managers. CIBC World Markets acted as co-lead manager, and Rodman & Renshaw was co-manager.

Taub sold $21.8 million worth of Omrix shares as part of the secondary offering. His remaining 16 percent stake is worth $89.9 million.

 

cleanshoe.net | DISCLAIMER NOTICE